Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease

Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis (SPMS) in adults Up to 80% of patients with relapsing remitting MS (RRMS) will develop SPMS(1); Mayzent addresses a ... Biopharmaceuticals, Neurology, FDA Novartis, Mayzent, siponimod, multiple sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news